Savara(US:SVRA) Globenewswireยท2025-09-21 11:14Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Savara Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Biologics License Application (BLA) for MOLBREEVI [4][6]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses exceeding $50,000 in Savara between March 7, 2024, and May 23, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Savara, with a deadline of November 7, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Savara and its executives made false statements regarding the MOLBREEVI BLA, including insufficient information about its chemistry and manufacturing, which likely affected FDA approval [6]. Group 2: Stock Performance and Impact - Following the announcement of a refusal to file letter from the FDA regarding the MOLBREEVI BLA on May 27, 2025, Savara's stock price dropped by $0.90 per share, or 31.69%, closing at $1.94 per share [7]. Group 3: Company Background and Recovery - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995, with offices in multiple states [5]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Savara's conduct [9].